PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
ESC Congress Rome 2016
FOURIER doesn't disappoint
Amgen announces positive topline results

Amgen has confirmed that the much-awaited FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial showed that treatment with the PCSK9 inhibitor evolocumab significantly reduced the risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease on optimized statin therapy.
Henry Ginsberg
PCSK9 Forum Editor Professor Henry Ginsberg (Columbia University, New York, USA) sums up the enthusiasm about these important results among the clinical community.

Read the report here »
Our popular therapeutic guide

Third edition coming soon updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

Read online »

Download now »

Forward to colleagues »
  New eBook
Click here to forward this email to a colleague
Questions & Answers
Why are new treatments needed?
Read the full answer and other questions on the PCSK9 Forum »
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2017. Please click here to unsubscribe from future mailings.